Cantor Fitzgerald Downgrades Dimension Therapeutics (DMTX) to Neutral

Cantor Fitzgerald downgraded Dimension Therapeutics (NASDAQ: DMTX) from Overweight to Neutral with a price target of $3.00 (from $32.00).

Analyst Elemer Piros commented, "We are lowering our rating to Neutral from Overweight and price target to $3 from $32, following initial results from Dimension's Phase 1/2 Study with DTX101 in Hemophilia B. Results highlighted that DTX101 will require additional optimization to be competitive with currently ongoing Hemophilia B gene therapy programs. While DTX101 was able to achieve meaningful peak FIX levels, these levels declined significantly in all patients. In addition, five of six patients demonstrated elevated levels of ALTs, which could hinder the company's ability to dose higher. Seeing the need for additional optimization for the hemophilia B program, we are moving to the sidelines and adjusting our price target."

For an analyst ratings summary and ratings history on Dimension Therapeutics click here. For more ratings news on Dimension Therapeutics click here.

Shares of Dimension Therapeutics closed at $4.25 yesterday.

You May Also Be Interested In

• Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
• Enovis Corp (ENOV) PT Lowered to $27 at BMO Capital
• Scotiabank Starts Webull (BULL) at Sector Outperform